PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Selective cytokine inhibitors - Market size and forecast 2018-2023 • Immunosuppressive antimetabolites - Market size and forecast 2018-2023 • Other drugs - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Novel techniques for kidney transplantation • Reimbursement policies for kidney transplantation • Increasing strategic alliances PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Astellas Pharma, Inc. • F. Hoffmann-La Roche Ltd. • Mylan NV • Novartis AG • Veloxis Pharmaceuticals A/S PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Vendors: Key offerings Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Selective cytokine inhibitors - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Selective cytokine inhibitors - Year-over-year growth 2019-2023 (%) Exhibit 22: Immunosuppressive antimetabolites - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Immunosuppressive antimetabolites - Year-over-year growth 2019-2023 (%) Exhibit 24: Other drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Other drugs - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Impact of drivers and challenges Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Astellas Pharma Inc. - Vendor overview Exhibit 51: Astellas Pharma Inc. - Business segments Exhibit 52: Astellas Pharma Inc. - Organizational developments Exhibit 53: Astellas Pharma Inc. - Geographic focus Exhibit 54: Astellas Pharma Inc. - Key offerings Exhibit 55: Astellas Pharma Inc. - Key customers Exhibit 56: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 57: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 58: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 59: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 60: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 61: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 62: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 63: Mylan NV - Vendor overview Exhibit 64: Mylan NV - Product segments Exhibit 65: Mylan NV - Organizational developments Exhibit 66: Mylan NV - Geographic focus Exhibit 67: Mylan NV - Segment focus Exhibit 68: Mylan NV - Key offerings Exhibit 69: Mylan NV - Key customers Exhibit 70: Novartis AG - Vendor overview Exhibit 71: Novartis AG - Business segments Exhibit 72: Novartis AG - Organizational developments Exhibit 73: Novartis AG - Geographic focus Exhibit 74: Novartis AG - Segment focus Exhibit 75: Novartis AG - Key offerings Exhibit 76: Novartis AG - Key customers Exhibit 77: Veloxis Pharmaceuticals A/S - Vendor overview Exhibit 78: Veloxis Pharmaceuticals A/S - Business segments Exhibit 79: Veloxis Pharmaceuticals A/S - Organizational developments Exhibit 80: Veloxis Pharmaceuticals A/S - Geographic focus Exhibit 81: Veloxis Pharmaceuticals A/S - Key offerings Exhibit 82: Veloxis Pharmaceuticals A/S - Key customers Exhibit 83: Validation techniques employed for market sizing Exhibit 84: Definition of market positioning of vendors

Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Mylan NV, Novartis AG, and Veloxis Pharmaceuticals A/S.